IL318777A - Heterocyclic compounds, compositions thereof, and methods of treatment therewith - Google Patents
Heterocyclic compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- IL318777A IL318777A IL318777A IL31877725A IL318777A IL 318777 A IL318777 A IL 318777A IL 318777 A IL318777 A IL 318777A IL 31877725 A IL31877725 A IL 31877725A IL 318777 A IL318777 A IL 318777A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- heterocyclic compounds
- treatment therewith
- therewith
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022111871 | 2022-08-11 | ||
| CN2022121125 | 2022-09-23 | ||
| CN2023079087 | 2023-03-01 | ||
| CN2023093212 | 2023-05-10 | ||
| PCT/CN2023/112168 WO2024032702A1 (en) | 2022-08-11 | 2023-08-10 | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318777A true IL318777A (en) | 2025-04-01 |
Family
ID=89850951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318777A IL318777A (en) | 2022-08-11 | 2023-08-10 | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240262848A1 (en) |
| EP (1) | EP4568974A4 (en) |
| JP (1) | JP2025528147A (en) |
| KR (1) | KR20250047379A (en) |
| CN (2) | CN121537411A (en) |
| AR (1) | AR130165A1 (en) |
| AU (1) | AU2023320914A1 (en) |
| CA (1) | CA3264226A1 (en) |
| CL (1) | CL2025000363A1 (en) |
| CO (1) | CO2025002940A2 (en) |
| IL (1) | IL318777A (en) |
| MX (1) | MX2025001680A (en) |
| TW (1) | TW202417454A (en) |
| WO (1) | WO2024032702A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023172737A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN121487738A (en) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | Compositions for inducing RAS GTP hydrolysis and their uses |
| KR20260019479A (en) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Combination therapy for RAS-related diseases or disorders |
| CN121194980A (en) * | 2023-05-16 | 2025-12-23 | 和记黄埔医药(上海)有限公司 | Tricyclic compounds and their uses |
| EP4724445A1 (en) | 2023-06-06 | 2026-04-15 | Kumquat Biosciences Inc. | Substituted heterocycles and uses thereof |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| EP4735451A1 (en) | 2023-06-30 | 2026-05-06 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| CN121889155A (en) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | RMC-6291 for the treatment of RAS protein-related diseases or disorders |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20250163079A1 (en) * | 2023-11-01 | 2025-05-22 | Incyte Corporation | Kras inhibitors |
| TW202539672A (en) * | 2024-02-06 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | Pyrimidine macrocyclic KRAS inhibitors |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| TW202615036A (en) * | 2024-07-31 | 2026-04-16 | 大陸商和記黃埔醫藥(上海)有限公司 | Tricyclic compounds and uses thereof |
| TW202615038A (en) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026098684A1 (en) * | 2024-11-11 | 2026-05-15 | 上海科州药物股份有限公司 | Heterocyclic compound as kras inhibitor, preparation therefor and therapeutic use thereof |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN114615981B (en) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | KRAS G12D inhibitors |
| CN112574224A (en) * | 2019-09-30 | 2021-03-30 | 上海迪诺医药科技有限公司 | KRAS G12C inhibitor and application thereof |
| WO2022170999A1 (en) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | Pyridine[4,3-d]pyrimidine compound |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CA3215949A1 (en) * | 2021-04-08 | 2022-10-13 | Genentech, Inc. | Oxazepine compounds and uses thereof in the treatment of cancer |
| WO2023172737A1 (en) * | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| KR20250034087A (en) * | 2022-07-09 | 2025-03-10 | 블로썸힐 테라퓨틱스, 인크. | Fusion-Ring KRAS Inhibitors for Disease Treatment |
| AU2023320565A1 (en) * | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
-
2023
- 2023-08-10 JP JP2025507408A patent/JP2025528147A/en active Pending
- 2023-08-10 AR ARP230102106A patent/AR130165A1/en unknown
- 2023-08-10 CN CN202511103125.1A patent/CN121537411A/en active Pending
- 2023-08-10 TW TW112130032A patent/TW202417454A/en unknown
- 2023-08-10 EP EP23851923.5A patent/EP4568974A4/en active Pending
- 2023-08-10 WO PCT/CN2023/112168 patent/WO2024032702A1/en not_active Ceased
- 2023-08-10 CN CN202380058002.3A patent/CN119677754A/en active Pending
- 2023-08-10 IL IL318777A patent/IL318777A/en unknown
- 2023-08-10 KR KR1020257007659A patent/KR20250047379A/en active Pending
- 2023-08-10 AU AU2023320914A patent/AU2023320914A1/en active Pending
- 2023-08-10 CA CA3264226A patent/CA3264226A1/en active Pending
-
2024
- 2024-03-06 US US18/597,844 patent/US20240262848A1/en active Pending
-
2025
- 2025-02-07 CL CL2025000363A patent/CL2025000363A1/en unknown
- 2025-02-10 MX MX2025001680A patent/MX2025001680A/en unknown
- 2025-03-06 CO CONC2025/0002940A patent/CO2025002940A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2025002940A2 (en) | 2025-03-27 |
| EP4568974A4 (en) | 2026-05-20 |
| CN119677754A (en) | 2025-03-21 |
| CL2025000363A1 (en) | 2025-06-06 |
| JP2025528147A (en) | 2025-08-26 |
| TW202417454A (en) | 2024-05-01 |
| AU2023320914A1 (en) | 2025-02-27 |
| MX2025001680A (en) | 2025-05-02 |
| CA3264226A1 (en) | 2024-02-15 |
| US20240262848A1 (en) | 2024-08-08 |
| EP4568974A1 (en) | 2025-06-18 |
| AR130165A1 (en) | 2024-11-13 |
| WO2024032702A1 (en) | 2024-02-15 |
| KR20250047379A (en) | 2025-04-03 |
| CN121537411A (en) | 2026-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3264226A1 (en) | Heterocyclic compounds, compositions thereof, and methods of treatment therewith | |
| IL288278A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| EP4171568A4 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| IL315099A (en) | Heterocyclic compounds and uses thereof | |
| EP4110369A4 (en) | Methods of treatment and related compositions | |
| IL312583A (en) | Composition for treatment and prevention of covid-19 | |
| EP4003246A4 (en) | Compositions and methods for treatment of presbyopia | |
| IL291548A (en) | Pediatric trazodone compositions and method of treatment thereof | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| IL314594A (en) | Heterocyclic compounds and methods of use | |
| IL288415A (en) | Compositions and methods for treatment of hemochromatosis | |
| EP4003341A4 (en) | Compositions and methods for treatment of presbyopia | |
| HK40124853A (en) | Heterocyclic compounds, compositions thereof, and methods of treatment therewith | |
| GB2607584B (en) | Composition and method of treatment | |
| GB202212451D0 (en) | Methods and compositions for the treatment of hemangioma | |
| HK40104701A (en) | Compounds, compositions and methods of treatment thereof | |
| GB2595502B (en) | Compounds, compositions and methods for the treatment or prevention of hair loss | |
| SI4334289T1 (en) | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | |
| HK40117615A (en) | Compositions and methods for treatment of epilepsies | |
| GB202016159D0 (en) | Compound, compositions and methods for the treatment of pain | |
| EP4359404A4 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| EP4359406A4 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40091354A (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| HK40068676A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| IL305890A (en) | Compositions and Methods for the Treatment of Alopecia |